$TYRA
Tyra Biosciences, Inc.

2022 Q4 Form 10-Q Financial Statement

#000095017022021937 Filed on November 03, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.618M $2.730M $1.154M
YoY Change 72.18% 136.57% 145.53%
% of Gross Profit
Research & Development $10.40M $10.92M $5.484M
YoY Change 43.45% 99.03% 194.52%
% of Gross Profit
Depreciation & Amortization $82.00K $82.00M $41.00M
YoY Change 64.0% 100.0% 156.25%
% of Gross Profit
Operating Expenses $15.02M $13.65M $6.638M
YoY Change 51.21% 105.56% 184.65%
Operating Profit -$13.65M -$6.638M
YoY Change 105.56% 184.65%
Interest Expense $2.156M $1.131M $2.000K
YoY Change 43020.0% 56450.0%
% of Operating Profit
Other Income/Expense, Net -$33.00K $1.136M -$5.000K
YoY Change 1000.0% -22820.0% -28.57%
Pretax Income -$12.90M -$12.51M -$6.643M
YoY Change 29.86% 88.3% 184.01%
Income Tax
% Of Pretax Income
Net Earnings -$12.90M -$12.51M -$6.643M
YoY Change 29.86% 88.3% 184.01%
Net Earnings / Revenue
Basic Earnings Per Share -$0.30 -$0.72
Diluted Earnings Per Share -$0.31 -$0.30 -$168.6K
COMMON SHARES
Basic Shares Outstanding 42.20M 41.97M 10.62M
Diluted Shares Outstanding 42.00M 9.164M

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $251.2M $263.2M $312.8M
YoY Change -16.87% -15.86%
Cash & Equivalents $251.2M $263.2M $312.8M
Short-Term Investments $0.00
Other Short-Term Assets $6.075M $4.260M $678.0K
YoY Change 224.0% 528.32%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $257.3M $267.5M $313.5M
YoY Change -15.38% -14.68%
LONG-TERM ASSETS
Property, Plant & Equipment $1.077M $1.146M $779.0K
YoY Change 4.87% 47.11%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $4.350M $3.872M $318.0K
YoY Change 1294.23% 1117.61%
Total Long-Term Assets $8.893M $8.514M $2.469M
YoY Change 236.35% 244.84%
TOTAL ASSETS
Total Short-Term Assets $257.3M $267.5M $313.5M
Total Long-Term Assets $8.893M $8.514M $2.469M
Total Assets $266.2M $276.0M $316.0M
YoY Change -13.21% -12.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.145M $2.747M $2.068M
YoY Change 91.15% 32.83%
Accrued Expenses $4.556M $2.742M $2.700M
YoY Change 51.01% 1.56%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change
Total Short-Term Liabilities $5.701M $5.489M $4.768M
YoY Change 57.66% 15.12%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $169.0K $226.0K $434.0K
YoY Change -53.95% -47.93%
Total Long-Term Liabilities $169.0K $226.0K $434.0K
YoY Change -53.95% -47.93%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.701M $5.489M $4.768M
Total Long-Term Liabilities $169.0K $226.0K $434.0K
Total Liabilities $8.352M $8.229M $6.239M
YoY Change 68.25% 31.9%
SHAREHOLDERS EQUITY
Retained Earnings -$95.70M -$82.80M -$30.44M
YoY Change 137.05% 172.0%
Common Stock $353.5M $350.6M $340.2M
YoY Change 3.34% 3.05%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $257.8M $267.8M $309.7M
YoY Change
Total Liabilities & Shareholders Equity $266.2M $276.0M $316.0M
YoY Change -13.21% -12.65%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$12.90M -$12.51M -$6.643M
YoY Change 29.86% 88.3% 184.01%
Depreciation, Depletion And Amortization $82.00K $82.00M $41.00M
YoY Change 64.0% 100.0% 156.25%
Cash From Operating Activities -$11.98M -$12.21M -$5.578M
YoY Change 32.7% 118.93% 163.74%
INVESTING ACTIVITIES
Capital Expenditures $21.00K -$48.00K -$256.0K
YoY Change -120.0% -81.25% 137.04%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $16.00K
YoY Change -100.0%
Cash From Investing Activities -$21.00K -$48.00K -$240.0K
YoY Change -80.0% -80.0% 122.22%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.000K 364.0K 183.4M
YoY Change -100.2% -99.8% -3057383.33%
NET CHANGE
Cash From Operating Activities -11.98M -12.21M -5.578M
Cash From Investing Activities -21.00K -48.00K -240.0K
Cash From Financing Activities 3.000K 364.0K 183.4M
Net Change In Cash -12.00M -11.90M 177.6M
YoY Change 12.75% -106.7% -8068.55%
FREE CASH FLOW
Cash From Operating Activities -$11.98M -$12.21M -$5.578M
Capital Expenditures $21.00K -$48.00K -$256.0K
Free Cash Flow -$12.00M -$12.16M -$5.322M
YoY Change 34.5% 128.56% 165.17%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1556000
dei Amendment Flag
AmendmentFlag
false
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001863127
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40800
dei Entity Registrant Name
EntityRegistrantName
TYRA BIOSCIENCES, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
83-1476348
dei Entity Address Address Line1
EntityAddressAddressLine1
2656 State Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Carlsbad
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92008
dei City Area Code
CityAreaCode
619
dei Local Phone Number
LocalPhoneNumber
728-4760
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
TYRA
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
42197431
dei Entity Listing Par Value Per Share
EntityListingParValuePerShare
0.0001
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
263211000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
302182000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4260000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1875000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
267471000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
304057000
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1000000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
243000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42632858
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1146000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1027000
CY2022Q3 tyra Right Of Use Asset
RightOfUseAsset
2496000
CY2021Q4 tyra Right Of Use Asset
RightOfUseAsset
1062000
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3872000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
312000
CY2022Q3 us-gaap Assets
Assets
275985000
CY2021Q4 us-gaap Assets
Assets
306701000
CY2022Q3 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
64000
CY2021Q4 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
47000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2747000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
599000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
127000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
202000
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2615000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2815000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
5489000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3616000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2514000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
981000
CY2022Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
226000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
367000
CY2022Q3 us-gaap Liabilities
Liabilities
8229000
CY2021Q4 us-gaap Liabilities
Liabilities
4964000
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42536183
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
42136971
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
41441135
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
4000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
350553000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
342104000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-82801000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-40371000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
267756000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
301737000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
275985000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
306701000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10915000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5484000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
32608000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13386000
CY2022Q3 us-gaap Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
173000
CY2021Q3 us-gaap Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
142000
us-gaap Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
570000
us-gaap Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
260000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2730000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1154000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11301000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2970000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
13645000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
6638000
us-gaap Operating Expenses
OperatingExpenses
43909000
us-gaap Operating Expenses
OperatingExpenses
16356000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-13645000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6638000
us-gaap Operating Income Loss
OperatingIncomeLoss
-43909000
us-gaap Operating Income Loss
OperatingIncomeLoss
-16356000
CY2022Q3 tyra Investment Income Interest Expense
InvestmentIncomeInterestExpense
1131000
CY2021Q3 tyra Investment Income Interest Expense
InvestmentIncomeInterestExpense
2000
tyra Investment Income Interest Expense
InvestmentIncomeInterestExpense
1496000
tyra Investment Income Interest Expense
InvestmentIncomeInterestExpense
8000
CY2022Q3 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
5000
CY2021Q3 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
7000
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
17000
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
16000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1136000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-5000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1479000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-8000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-12509000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-6643000
us-gaap Net Income Loss
NetIncomeLoss
-42430000
us-gaap Net Income Loss
NetIncomeLoss
-16364000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.30
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.30
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.72
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.72
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.02
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.02
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.63
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.63
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41997195
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41997195
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9164003
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9164003
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41777052
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41777052
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4504997
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4504997
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-13638000
CY2021Q1 tyra Issuance Of Common Stock Under Benefit Plans
IssuanceOfCommonStockUnderBenefitPlans
86000
CY2021Q1 tyra Vesting Of Shares Of Common Stock Subject To Repurchase
VestingOfSharesOfCommonStockSubjectToRepurchase
65000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
174000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-4209000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-17522000
CY2021Q2 tyra Issuance Of Common Stock Under Benefit Plans
IssuanceOfCommonStockUnderBenefitPlans
1000
CY2021Q2 tyra Vesting Of Shares Of Common Stock Subject To Repurchase
VestingOfSharesOfCommonStockSubjectToRepurchase
28000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
338000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-5512000
CY2021Q2 us-gaap Shares Outstanding
SharesOutstanding
2374351
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-22667000
CY2021Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
157274000
CY2021Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
181220000
CY2021Q3 tyra Issuance Of Common Stock Under Benefit Plans
IssuanceOfCommonStockUnderBenefitPlans
1000
CY2021Q3 tyra Vesting Of Shares Of Common Stock Subject To Repurchase
VestingOfSharesOfCommonStockSubjectToRepurchase
39000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
507000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-6643000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
309731000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
301737000
CY2022Q1 tyra Issuance Of Common Stock Under Benefit Plans
IssuanceOfCommonStockUnderBenefitPlans
238000
CY2022Q1 tyra Vesting Of Shares Of Common Stock Subject To Repurchase
VestingOfSharesOfCommonStockSubjectToRepurchase
63000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3972000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-14826000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
291184000
CY2022Q2 tyra Issuance Of Common Stock Under Benefit Plans
IssuanceOfCommonStockUnderBenefitPlans
34000
CY2022Q2 tyra Vesting Of Shares Of Common Stock Subject To Repurchase
VestingOfSharesOfCommonStockSubjectToRepurchase
42000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2688000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-15095000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
278853000
CY2022Q3 tyra Issuance Of Common Stock Under Benefit Plans
IssuanceOfCommonStockUnderBenefitPlans
356000
CY2022Q3 tyra Vesting Of Shares Of Common Stock Subject To Repurchase
VestingOfSharesOfCommonStockSubjectToRepurchase
37000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1019000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-12509000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
267756000
us-gaap Net Income Loss
NetIncomeLoss
-42430000
us-gaap Net Income Loss
NetIncomeLoss
-16364000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
214000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
90000
us-gaap Share Based Compensation
ShareBasedCompensation
7679000
us-gaap Share Based Compensation
ShareBasedCompensation
1019000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-3000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-3000
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
5945000
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
917000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2150000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1396000
tyra Increase Decrease In Right Of Use Assets And Lease Liabilities Net
IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet
24000
tyra Increase Decrease In Right Of Use Assets And Lease Liabilities Net
IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet
56000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-38305000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14717000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
538000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
556000
us-gaap Proceeds From Sale Of Other Property Plant And Equipment
ProceedsFromSaleOfOtherPropertyPlantAndEquipment
0
us-gaap Proceeds From Sale Of Other Property Plant And Equipment
ProceedsFromSaleOfOtherPropertyPlantAndEquipment
16000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-538000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-540000
tyra Payment Of Deferred Offering Costs
PaymentOfDeferredOfferingCosts
0
tyra Payment Of Deferred Offering Costs
PaymentOfDeferredOfferingCosts
-182729000
tyra Proceeds From Issuance Of Common Stock Under Benefit Plans
ProceedsFromIssuanceOfCommonStockUnderBenefitPlans
629000
tyra Proceeds From Issuance Of Common Stock Under Benefit Plans
ProceedsFromIssuanceOfCommonStockUnderBenefitPlans
513000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
0
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
9000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
629000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
312856000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-38214000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
297599000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
302425000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15467000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
264211000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
313066000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
263211000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
312823000
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
1000000
CY2021Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
243000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
264211000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
313066000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1238000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
9000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
17000
tyra Deferred Offering Costs Included In Accrued Expenses
DeferredOfferingCostsIncludedInAccruedExpenses
0
tyra Deferred Offering Costs Included In Accrued Expenses
DeferredOfferingCostsIncludedInAccruedExpenses
1509000
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2018-08-02
CY2021Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.0000025974
CY2021Q3 tyra Increase In Authorized Share Due To Forward Stock Split
IncreaseInAuthorizedShareDueToForwardStockSplit
50000000
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1000000.0
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
200000
CY2022Q3 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
0
CY2021Q4 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
0
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1196000
CY2022Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
379000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
169000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1146000
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2615000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2815000
CY2022Q3 tyra Less Weighted Average Unvested Common Stock Issued Upon Early Exercise Of Common Stock Options
LessWeightedAverageUnvestedCommonStockIssuedUponEarlyExerciseOfCommonStockOptions
-440194
CY2021Q3 tyra Less Weighted Average Unvested Common Stock Issued Upon Early Exercise Of Common Stock Options
LessWeightedAverageUnvestedCommonStockIssuedUponEarlyExerciseOfCommonStockOptions
-784258
tyra Less Weighted Average Unvested Common Stock Issued Upon Early Exercise Of Common Stock Options
LessWeightedAverageUnvestedCommonStockIssuedUponEarlyExerciseOfCommonStockOptions
-506922
tyra Less Weighted Average Unvested Common Stock Issued Upon Early Exercise Of Common Stock Options
LessWeightedAverageUnvestedCommonStockIssuedUponEarlyExerciseOfCommonStockOptions
-694252
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41997195
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41997195
CY2022Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1525000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1027000
CY2022Q3 us-gaap Depreciation
Depreciation
82000000
us-gaap Depreciation
Depreciation
214000000
CY2021Q3 us-gaap Depreciation
Depreciation
41000000
us-gaap Depreciation
Depreciation
90000000
CY2022Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
1150000
CY2021Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
1278000
CY2022Q3 tyra Accrued Research And Development
AccruedResearchAndDevelopment
1100000
CY2021Q4 tyra Accrued Research And Development
AccruedResearchAndDevelopment
1257000
CY2022Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
121000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
61000
CY2022Q3 tyra Accrued Other General And Administrative Fees
AccruedOtherGeneralAndAdministrativeFees
244000
CY2021Q4 tyra Accrued Other General And Administrative Fees
AccruedOtherGeneralAndAdministrativeFees
219000
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9164003
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9164003
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41777052
CY2022Q3 tyra Common Stock Options Granted And Outstanding
CommonStockOptionsGrantedAndOutstanding
5948170
CY2021Q4 tyra Common Stock Options Granted And Outstanding
CommonStockOptionsGrantedAndOutstanding
3771516
CY2022Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
10991285
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
8535790
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3771516
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.18
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y3M18D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
28901000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2630877
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
7.67
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
50756
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.98
tyra Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Expired
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpired
-121262
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
16.64
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
282205
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
16.18
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5948170
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.95
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y1M6D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
18806000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1262635
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
6.56
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y4M24D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
6475000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
5948170
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
7.95
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P9Y1M6D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
18806000
CY2022Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
13000000000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41777052
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4504997
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4504997
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.30
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.30
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.72
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1019000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
508000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7679000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1019000
CY2022Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
28100000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y10M24D
CY2022Q3 tyra Provision Related To Repurchase Of Early Exercised Options
ProvisionRelatedToRepurchaseOfEarlyExercisedOptions
368127
CY2021Q4 tyra Provision Related To Repurchase Of Early Exercised Options
ProvisionRelatedToRepurchaseOfEarlyExercisedOptions
599878
CY2022Q3 tyra Liability Related To Repurchase Of Early Exercised Options
LiabilityRelatedToRepurchaseOfEarlyExercisedOptions
200000
CY2021Q4 tyra Liability Related To Repurchase Of Early Exercised Options
LiabilityRelatedToRepurchaseOfEarlyExercisedOptions
400000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-12509000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-6643000
us-gaap Net Income Loss
NetIncomeLoss
-42430000
us-gaap Net Income Loss
NetIncomeLoss
-16364000
CY2022Q3 us-gaap Weighted Average Basic Shares Outstanding Pro Forma
WeightedAverageBasicSharesOutstandingProForma
42646810
CY2021Q3 us-gaap Weighted Average Basic Shares Outstanding Pro Forma
WeightedAverageBasicSharesOutstandingProForma
10621868
us-gaap Weighted Average Basic Shares Outstanding Pro Forma
WeightedAverageBasicSharesOutstandingProForma
42614902
us-gaap Weighted Average Basic Shares Outstanding Pro Forma
WeightedAverageBasicSharesOutstandingProForma
5984285
CY2022Q3 tyra Less Weighted Average Unvested Founder Shares Of Common Stock
LessWeightedAverageUnvestedFounderSharesOfCommonStock
-209421
CY2021Q3 tyra Less Weighted Average Unvested Founder Shares Of Common Stock
LessWeightedAverageUnvestedFounderSharesOfCommonStock
-673607
tyra Less Weighted Average Unvested Founder Shares Of Common Stock
LessWeightedAverageUnvestedFounderSharesOfCommonStock
-330928
tyra Less Weighted Average Unvested Founder Shares Of Common Stock
LessWeightedAverageUnvestedFounderSharesOfCommonStock
-785036
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.72
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.02
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.02
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.63
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.63
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6444057
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3954858
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
100000
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
100000
us-gaap Operating Lease Cost
OperatingLeaseCost
200000
us-gaap Operating Lease Cost
OperatingLeaseCost
300000
CY2022Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
100000
CY2021Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
100000
us-gaap Operating Lease Payments
OperatingLeasePayments
200000
us-gaap Operating Lease Payments
OperatingLeasePayments
200000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
73000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
299000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
309000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
317000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
327000
CY2022Q3 tyra Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
2378000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
3703000
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1062000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
2641000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
127000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2514000
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P10Y9M18D
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y7M6D
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0650
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0750

Files In Submission

Name View Source Status
0000950170-22-021937-index-headers.html Edgar Link pending
0000950170-22-021937-index.html Edgar Link pending
0000950170-22-021937.txt Edgar Link pending
0000950170-22-021937-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tyra-20220930.htm Edgar Link pending
tyra-20220930.xsd Edgar Link pending
tyra-ex31_1.htm Edgar Link pending
tyra-ex31_2.htm Edgar Link pending
tyra-ex32_1.htm Edgar Link pending
tyra-ex32_2.htm Edgar Link pending
tyra-20220930_cal.xml Edgar Link unprocessable
tyra-20220930_def.xml Edgar Link unprocessable
tyra-20220930_lab.xml Edgar Link unprocessable
tyra-20220930_pre.xml Edgar Link unprocessable
tyra-20220930_htm.xml Edgar Link completed